174 related articles for article (PubMed ID: 12784774)
1. Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks.
De Caterina R
Ital Heart J; 2003 Apr; 4(4):228-31. PubMed ID: 12784774
[TBL] [Abstract][Full Text] [Related]
2. Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Walker CW; Dawley CA; Fletcher SF
Am Fam Physician; 2007 Dec; 76(11):1643-5. PubMed ID: 18092705
[No Abstract] [Full Text] [Related]
3. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Arjomand H; Cohen M; Ezekowitz MD
J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
[TBL] [Abstract][Full Text] [Related]
4. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
[TBL] [Abstract][Full Text] [Related]
5. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
6. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
Temizhan A
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Spinler SA
Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
[TBL] [Abstract][Full Text] [Related]
8. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Peters RJ; Mehta SR; Fox KA; Zhao F; Lewis BS; Kopecky SL; Diaz R; Commerford PJ; Valentin V; Yusuf S;
Circulation; 2003 Oct; 108(14):1682-7. PubMed ID: 14504182
[TBL] [Abstract][Full Text] [Related]
9. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland.
Rodondi N; Cornuz J; Marques-Vidal P; Butler J; Hayoz D; Pécoud A; Paccaud F; Waeber G; Vollenweider P
Prev Med; 2008 Feb; 46(2):137-44. PubMed ID: 17904211
[TBL] [Abstract][Full Text] [Related]
10. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
Terpening C
J Am Board Fam Med; 2009; 22(1):51-6. PubMed ID: 19124633
[TBL] [Abstract][Full Text] [Related]
11. Ethical considerations in relation to aspirin prophylaxis.
Morgan G
Qual Prim Care; 2008; 16(6):433-40. PubMed ID: 19094419
[TBL] [Abstract][Full Text] [Related]
12. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
13. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
14. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
Hennekens CH; Sechenova O; Hollar D; Serebruany VL
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
[TBL] [Abstract][Full Text] [Related]
15. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
[TBL] [Abstract][Full Text] [Related]
16. [The role of aspirin in the primary prevention of cardiovascular disease].
Rodondi N; Cornuz J
Rev Med Suisse; 2006 Mar; 2(56):646-51. PubMed ID: 16597054
[TBL] [Abstract][Full Text] [Related]
17. [Coronary disease: benefits of aspirin. What dose for which disease?].
Michel PL
Ann Cardiol Angeiol (Paris); 1994 Apr; 43(4):204-10. PubMed ID: 8024235
[TBL] [Abstract][Full Text] [Related]
18. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
19. Low-dose aspirin for primary prevention of cardiovascular disease.
Bredie SJ; Wollersheim H; Verheugt FW; Thien T
Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
[TBL] [Abstract][Full Text] [Related]
20. Weighing the benefits and risks of aspirin for primary prevention of vascular disease.
Garg MK
J Assoc Physicians India; 2010 May; 58():331. PubMed ID: 21117359
[No Abstract] [Full Text] [Related]
[Next] [New Search]